FY2025 EPS Estimates for CG Oncology Decreased by Analyst

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share estimate for CG Oncology to ($2.19), a decrease from the previous estimate of ($1.83).
• The consensus estimate for CG Oncology's current full-year earnings stands at ($1.31) per share, indicating a broader downward trend in earnings estimates.
• CG Oncology has received a mix of ratings from analysts, with a consensus rating of "Moderate Buy" and a target price averaging $55.30.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of CG Oncology in a report issued on Monday, August 11th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($2.19) per share for the year, down from their previous estimate of ($1.83). Cantor Fitzgerald currently has a "Overweight" rating and a $75.00 target price on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share. Cantor Fitzgerald also issued estimates for CG Oncology's FY2026 earnings at ($3.80) EPS.

Several other analysts also recently commented on the company. JPMorgan Chase & Co. initiated coverage on CG Oncology in a research note on Friday, May 2nd. They set an "overweight" rating and a $41.00 price objective for the company. The Goldman Sachs Group raised CG Oncology to a "strong-buy" rating and set a $40.00 price objective for the company in a research note on Thursday, July 10th. Royal Bank Of Canada reduced their price objective on CG Oncology from $68.00 to $53.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. Finally, Morgan Stanley upped their price objective on CG Oncology from $52.00 to $56.00 and gave the company an "overweight" rating in a research note on Tuesday, June 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $55.30.

CG Oncology Stock Up 1.7%

CGON traded up $0.43 on Wednesday, hitting $26.13. 516,049 shares of the company traded hands, compared to its average volume of 995,382. The company has a 50 day moving average of $26.16 and a 200-day moving average of $25.44. The stock has a market capitalization of $1.99 billion, a PE ratio of -14.76 and a beta of 0.87. CG Oncology has a 12-month low of $14.80 and a 12-month high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in shares of CG Oncology by 443.5% in the 4th quarter. JPMorgan Chase & Co. now owns 168,866 shares of the company's stock worth $4,843,000 after acquiring an additional 137,795 shares during the period. Geode Capital Management LLC grew its holdings in shares of CG Oncology by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 1,156,670 shares of the company's stock worth $33,181,000 after acquiring an additional 78,143 shares during the period. Wells Fargo & Company MN grew its holdings in shares of CG Oncology by 45.3% in the 4th quarter. Wells Fargo & Company MN now owns 28,234 shares of the company's stock worth $810,000 after acquiring an additional 8,803 shares during the period. Federated Hermes Inc. acquired a new stake in shares of CG Oncology in the 4th quarter worth approximately $172,000. Finally, Invesco Ltd. grew its holdings in shares of CG Oncology by 75.7% in the 4th quarter. Invesco Ltd. now owns 27,069 shares of the company's stock worth $776,000 after acquiring an additional 11,662 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Leonard E. Post sold 2,000 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $28.00, for a total transaction of $56,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.